Vgamma9 Vdelta2 T cell (Vg9Vd2)

Vgamma9 Vdelta2 T cells are the predominant subset of gamma-delta (γδ) T cells in human peripheral blood, acting as a critical bridge between innate and adaptive immunity (Vantourout & Hayday, Nature Reviews Immunology, 2013). These cells are unique because they recognize non-peptidic phosphoantigens, such as isopentenyl pyrophosphate (IPP), in a Major Histocompatibility Complex (MHC)-independent manner via the Vγ9Vδ2 T-cell receptor (TCR). This recognition is mediated by the butyrophilin family proteins, specifically BTN3A1 and BTN2A1, which act as molecular sensors for intracellular metabolic changes (Rigau et al., Science, 2020). Upon activation, Vgamma9 Vdelta2 T cells exhibit potent cytotoxic activity and secrete pro-inflammatory cytokines like IFN-γ and TNF-α to eliminate infected or transformed cells. In therapeutic contexts, Vgamma9 Vdelta2 T cells are targeted primarily for oncology and infectious diseases. Drugs such as aminobisphosphonates (e.g., Zoledronic acid) indirectly activate these cells by inhibiting the mevalonate pathway, leading to the accumulation of IPP (Kunzmann et al., Blood, 2000). Modern approaches include the development of 'Gammabody' bispecific antibodies (e.g., LAVA-051, LAVA-1207) that specifically engage the Vγ9 TCR to redirect these cells toward tumor cells expressing antigens like CD1d or PSMA (LAVA Therapeutics, 2023). Because they do not require MHC matching, Vgamma9 Vdelta2 T cells are also being explored for 'off-the-shelf' allogeneic cell therapies, offering a lower risk of graft-versus-host disease compared to traditional alpha-beta T cells.

Other names

Vγ9Vδ2 T cellsVg9Vd2 T lymphocytesGamma-delta T cell subsetPhosphoantigen-reactive T cellsVgamma9Vdelta2 T-lymphocyte

Activation occurs via the Vgamma9 Vdelta2 TCR recognizing conformational changes in Butyrophilin 3A1 (BTN3A1) and Butyrophilin 2A1 (BTN2A1) induced by intracellular phosphoantigens. Bispecific antibodies engage the Vgamma9 chain to cross-link the T cell with tumor-associated antigens.